
FIRST WAVE BIOP.NEW-,0001
Action · US33749P4081 · FWBI · A3E2F2 (XNCM)
0,46 EUR
06.06.2025 22:14
Cours actuels de FIRST WAVE BIOP.NEW-,0001
Bourse | Ticker | Devise | Dernier échange | Cours | Variation journalière |
---|---|---|---|---|---|
![]() NASDAQ |
ENTO
|
USD
|
06.06.2025 22:14
|
0,52 USD
| 0,47 USD
+10,21 %
|
Performance
Jour | Semaine | Mois | 3 mois | 6 mois | 1 an | 5 ans |
---|---|---|---|---|---|---|
0,00 % | 29,36 % | 50,18 % | -14,89 % | -40,94 % | -80,47 % | -100,00 % |
Profil de l'entreprise pour FIRST WAVE BIOP.NEW-,0001 Action
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties; and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.
Données de l'entreprise
Nom FIRST WAVE BIOP.NEW-,0001
Société First Wave BioPharma, Inc.
Symbole FWBI
Site web
https://www.firstwavebio.com
Marché d'origine
Frankfurt

WKN A3E2F2
ISIN US33749P4081
Type de titre Action
Secteur Healthcare
Industrie Biotechnology
PDG Mr. James R. Sapirstein M.B.A., R.Ph.
Pays États-Unis d'Amérique
Devise EUR
Employés 0,0 T
Adresse 777 Yamato Road, 33431 Boca Raton
Date d'introduction en bourse 2016-10-11
Changements d'identifiant
Date | De | À |
---|---|---|
22.09.2021 | AZRX | FWBI |
17.05.2024 | FWBI | ENTO |
22.09.2021 | AZRX | FWBI |
Symboles boursiers
Nom | Symbole |
---|---|
NASDAQ | ENTO |
NASDAQ | FWBI |
Autres actions
Les investisseurs qui détiennent FIRST WAVE BIOP.NEW-,0001 ont également les actions suivantes dans leur portefeuille :
La plateforme financière MoneyPeak suit et analyse les investissements et les portefeuilles.
Du dépôt de titres à l'achat de crypto.
Utile, simple et gratuit. Actions, ETF, ETC, ETN, indices, fonds, obligations, certificats, devises, options, droits de souscription.
Utile, simple et gratuit. Actions, ETF, ETC, ETN, indices, fonds, obligations, certificats, devises, options, droits de souscription.